Choice Institutional Equities has initiated coverage on Senores Pharma with a ₹1,700 target. The brokerage expects 30% revenue growth driven by new product launches and the integration of acquisitions, Zoraya and Amerisyn. Investors may track the company’s ability to manage margins while scaling these new business segments.
Choice Institutional Equities has started coverage on Senores Pharma with a target price of ₹1,700, reflecting a positive outlook on the company's growth strategy. The brokerage anticipates that the firm will grow its revenue at a compound annual growth rate of 30% over the next three years. This growth is expected to be driven by new product launches and the successful integration of its recent acquisitions, Zoraya and Amerisyn.
The company has been actively working on several Abbreviated New Drug Applications (ANDA). These filings are essential for pharmaceutical firms to bring generic versions of existing drugs to the US market. By expanding into the controlled-substance market, the company aims to diversify its revenue streams and reduce reliance on its traditional product portfolio.
A critical factor in the company’s expansion strategy is its recent PIC/S (Pharmaceutical Inspection Co-operation Scheme) approval. This is an international recognition of quality standards that allows manufacturers to export products to highly regulated countries with fewer hurdles. With over 944 product registrations already in its portfolio, the company is building a foundation to scale its operations across emerging markets.
Management has projected EBITDA margins near 30%. However, the brokerage maintains a slightly more conservative view, projecting margins between 28% and 29% for fiscal years 2027 and 2028. This adjustment reflects the initial costs of scaling operations and the integration expenses associated with the Zoraya and Amerisyn business units. Investors may note that as these acquired businesses mature, there could be potential for margin improvement.
The outlook for the company involves navigating the risks associated with integrating new business units and complying with strict regulatory requirements for new product approvals. While the brokerage points to a low price-to-earnings-growth ratio as a potential entry point, the company's future performance will depend on the successful execution of its product pipeline and the sustained performance of its core pharmaceutical segments. Investors may monitor the actual delivery of these new products and the trend in profitability margins in the upcoming quarters.